Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 1.23% as of August 28, 2025, with mixed performance among constituent stocks [3] - The Hang Seng Medical ETF (513060) fell by 1.15%, with a latest price of 0.69 yuan, but showed a 6.26% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) dropped by 1.02%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 0.81% to 0.98 yuan [4] Company Highlights - Innovent Biologics reported a 50.6% year-on-year revenue increase to 5.95 billion yuan for the first half of 2025, achieving a gross margin of 86% and a net profit of 830 million yuan, driven by pipeline expansion in oncology and new product launches [4] - The company has over 2 billion USD in cash reserves to support future innovation pipeline advancements [4] Policy and Industry Developments - The Ministry of Commerce and Jiangsu Provincial Government issued a plan to enhance the biopharmaceutical industry in Jiangsu Free Trade Zone by 2030, focusing on large molecule biologics, cell and gene therapy, and innovative medical devices [5] - Recent market pressure on the pharmaceutical sector was noted, with the Hang Seng Healthcare Index dropping over 2.1%, influenced by U.S. tariff proposals on imported drugs that could disrupt the global pharmaceutical industry [5] Analyst Insights - Analysts suggest that the recent decline in the Hong Kong pharmaceutical sector is a short-term fluctuation and does not alter the long-term industry outlook, with ongoing favorable policies expected to drive more cross-border business development transactions [6] - The Chinese innovative drug assets are gaining international recognition, presenting structural opportunities in the medium to long term [6] ETF Performance and Metrics - The Hang Seng Medical ETF has seen a significant increase in scale by 46.87 million yuan this month, ranking in the top third among comparable funds [8] - The ETF's share count increased by 92.5 million shares over the past week, also ranking in the top third [9] - The ETF recorded a net inflow of 74.96 million yuan recently, with a total of 65.92 million yuan accumulated over the last five trading days [10] - The ETF's financing net purchase reached 2.5072 million yuan this month, with a financing balance of 268 million yuan [11] Risk and Return Metrics - The Hang Seng Medical ETF has achieved a 48.60% net value increase over the past two years, with a maximum monthly return of 28.34% since inception [11] - The ETF's Sharpe ratio for the past year is 2.41, indicating strong risk-adjusted returns [12] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.63% year-to-date [13] Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Medical ETF is 30.9, which is below the historical average, indicating a potentially undervalued position [15]

Market Overview - On August 27, the Hang Seng Index fell by 1.27%, closing at 25,201.76 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 15.371 billion [1][2] Trading Activity - The total trading volume for the Stock Connect on August 27 was HKD 191.172 billion, with a net purchase of HKD 15.371 billion [1] - The Shanghai Stock Connect had a trading volume of HKD 118.378 billion and a net purchase of HKD 9.005 billion, while the Shenzhen Stock Connect had a trading volume of HKD 72.794 billion and a net purchase of HKD 6.366 billion [1] Active Stocks - In the Shanghai Stock Connect, the most actively traded stock was SMIC, with a trading volume of HKD 6.799 billion, followed by Alibaba and Tencent, with trading volumes of HKD 4.360 billion and HKD 4.078 billion, respectively [1][2] - In terms of net buying, the top stock was the Tracker Fund of Hong Kong (盈富基金), with a net purchase of HKD 3.056 billion, despite its closing price dropping by 1.23% [1] - SMIC recorded the highest net selling amount of HKD 586 million, while its closing price increased by 0.09% [1][2] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, SMIC also led in trading volume with HKD 5.356 billion, followed by Alibaba and the Tracker Fund of Hong Kong, with trading volumes of HKD 3.473 billion and HKD 2.502 billion, respectively [2] - The Tracker Fund of Hong Kong had a net purchase of HKD 2.494 billion, while Xiaomi Group recorded the highest net selling amount of HKD 300 million, with its closing price down by 0.56% [2]

Group 1 - The company, 康方生物, announced a conditional agreement for a placement of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.62% of the existing share capital as of the announcement date [1] - The placement price reflects a discount of about 4.75% compared to the closing price of HKD 157.00 on August 27, 2025 [1] - The estimated total gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion after deducting commissions and related expenses [1] Group 2 - The board was informed that Dr. 夏瑜 and Dr. 李百勇, as sellers, entered into a secondary placement agreement to sell a total of 3 million existing shares, representing about 0.33% of the total issued shares as of the announcement date [2]

Group 1 - The company, CanSino Biologics (康方生物), announced a conditional agreement for a primary placement of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.62% of the company's issued share capital as of the announcement date [1] - The placement price reflects a discount of about 4.75% compared to the closing price of HKD 157.00 on August 27, 2025, the last trading day before the placement agreement [1] - The estimated total gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion after deducting commissions and other related expenses [1] Group 2 - The board was informed that Dr. Xia Yu and Dr. Li Baiyong, as sellers, entered into a secondary placement agreement on August 28, 2025, to sell a total of 3 million existing shares, representing about 0.33% of the total issued shares as of the announcement date [2]

Core Insights - The article highlights the top short-selling stocks in the market, indicating significant investor sentiment and potential market movements [1][2][3] Short-Selling Ratios - AIA Group Limited (友邦保险-R) has the highest short-selling ratio at 100.00%, followed by JD Health (京东健康-R) at 93.01% and Anta Sports (安踏体育-R) at 92.84% [1][2] - Other notable mentions include BYD Company Limited (比亚迪股份-R) with a short-selling ratio of 90.97% and Tencent Holdings (腾讯控股-R) at 82.28% [2] Short-Selling Amounts - Meituan (美团-W) leads in short-selling amounts with 3.359 billion, followed by Alibaba Group (阿里巴巴-SW) at 3.259 billion and Tencent Holdings at 2.386 billion [1][3] - Other companies with significant short-selling amounts include Kuaishou Technology (快手-W) at 1.351 billion and SMIC (中芯国际) at 1.308 billion [3] Deviation Values - Tencent Holdings (腾讯控股-R) has the highest deviation value at 44.16%, indicating a significant difference from its average short-selling ratio over the past 30 days [1][3] - AIA Group Limited (友邦保险-R) follows with a deviation value of 36.56%, and China Resources Beer (华润啤酒-R) at 36.35% [1][3]

Group 1 - The core announcement is that 康方生物 (Kangfang Biologics) has entered into a placement agreement with Morgan Stanley to issue 23.55 million shares at a price of HKD 149.54 per share, representing a discount of approximately 4.75% from the closing price of HKD 157.00 on August 27 [1][2] - The placement shares will account for about 2.62% of the company's existing share capital and approximately 2.56% of the enlarged share capital post-placement [1] - The estimated gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion [2] Group 2 - The net proceeds from the placement will be allocated as follows: 80% for global and China innovation R&D pipeline and infrastructure development, 10% for commercialization of existing approved products, and 10% for general corporate purposes [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9926） 根據一般授權配售新股 ...

Key Points - The top three companies with net inflows of southbound funds are Alibaba-W (09988) with 581 million, Kangfang Biotech (09926) with 541 million, and Hong Kong Stock Exchange (00388) with 434 million [1] - The top three companies with net outflows of southbound funds are Yingfu Fund (02800) with -2.396 billion, Xiaomi Group-W (01810) with -1.524 billion, and SMIC (00981) with -845 million [1] - In terms of net inflow ratios, the top three companies are Quan Feng Holdings (02285) at 51.60%, Sen Song International (02155) at 49.91%, and GX China (03040) at 43.94% [1] - The top three companies with the highest net outflow ratios are Yihai International (01579) at -51.63%, Zhou Hei Ya (01458) at -49.54%, and Kangji Medical (09997) at -46.09% [1] Net Inflow Rankings - Alibaba-W (09988) had a net inflow of 581 million, representing a 2.88% increase in closing price to 124.500 [2] - Kangfang Biotech (09926) saw a net inflow of 541 million, with a closing price of 169.500, down 4.18% [2] - Hong Kong Stock Exchange (00388) experienced a net inflow of 434 million, closing at 462.800, up 3.30% [2] - Kuaishou-W (01024) had a net inflow of 428 million, closing at 78.750, up 5.14% [2] - Horizon Robotics-W (09660) recorded a net inflow of 401 million, closing at 7.760, up 1.31% [2] Net Outflow Rankings - Yingfu Fund (02800) had the largest net outflow of -2.396 billion, with a closing price of 26.360, up 2.01% [2] - Xiaomi Group-W (01810) experienced a net outflow of -1.524 billion, closing at 53.500, up 1.81% [2] - SMIC (00981) saw a net outflow of -845 million, with a closing price of 57.800, up 1.58% [2] - CNOOC (00883) had a net outflow of -708 million, closing at 18.830, up 0.53% [2] - Pop Mart (09992) recorded a net outflow of -418 million, closing at 326.600, up 1.94% [2] Net Inflow Ratio Rankings - Quan Feng Holdings (02285) had a net inflow ratio of 51.60%, with a net inflow of 24.33 million, closing at 24.300, up 5.29% [3] - Sen Song International (02155) recorded a net inflow ratio of 49.91%, with a net inflow of 54.68 million, closing at 10.900, up 1.68% [3] - GX China (03040) had a net inflow ratio of 43.94%, with a net inflow of 1.29 million, closing at 37.820, up 2.55% [3] Net Outflow Ratio Rankings - Yihai International (01579) had a net outflow ratio of -51.63%, with a net outflow of -69.47 million, closing at 14.780, up 4.23% [3] - Zhou Hei Ya (01458) recorded a net outflow ratio of -49.54%, with a net outflow of -20.12 million, closing at 2.570, up 2.80% [3] - Kangji Medical (09997) had a net outflow ratio of -46.09%, with a net outflow of -30.83 million, closing at 8.680, up 0.35% [3]

Summary of Key Points from the Conference Call of 康方生物 Company Overview - 康方生物 is advancing in the field of tumor immunotherapy, entering the 2.0 era with products like 卡度尼利 and 伊沃西, while actively exploring the ADC sector and various combination therapies [2][6][8]. Financial Performance - In the first half of 2025, 康方生物 achieved a total revenue of 14.1 billion RMB, with a commercial sales increase of 49% year-on-year [3][49]. - The gross profit from commercial sales was 11.1 billion RMB, a 20% increase from 8.89 billion RMB in the same period last year [50]. - R&D expenses rose by 23% to 7.3 billion RMB, while cash reserves stood at 71.38 billion RMB [50][13]. Clinical and Commercial Achievements - Significant clinical results were reported for AK112, which showed positive overall survival (OS) in EGFR TKI-resistant indications, marking it as the first IO drug to achieve such results globally [4][11]. - Multiple phase III clinical trials for 卡度尼利 have been initiated, covering various cancers including lung, gastric, liver, and cervical cancers [4][5]. - The final analysis of 伊沃西 (Harmony A) demonstrated statistically significant OS results, reinforcing its market position [2][4]. Product Pipeline and Development - 康方生物 has several products in the pipeline, with multiple autoimmune products expected to be approved between late 2024 and early 2025 [2][4]. - The company is focusing on ADC development, with two dual-target ADC products entering clinical stages [4][10]. - The company has independently conducted international multi-center clinical trials for 派安普利, showcasing its capabilities in global registration systems [2][10]. Strategic Direction - 康方生物 aims to enhance its product offerings in tumor immunotherapy and ADC, with plans to combine PD-1 with ADC to improve efficacy and reduce toxicity [6][8]. - The company is expanding its international presence, with clinical data showing consistency between Chinese and global data, indicating the potential for global patient treatment [7][8]. Market Position and Future Outlook - The company has established a strong commercial presence, with its dual antibody products included in the national medical insurance directory, covering over 2,000 hospitals [11][20]. - Future plans include expanding the market for non-tumor drugs and enhancing the commercialization of existing products like AK112 and AK104 [9][20]. - 康方生物 is committed to maintaining a balance between R&D investment and commercial operations, aiming to reduce R&D expenses as a percentage of sales over time [63][62]. Challenges and Considerations - The company reported a loss of 588 million RMB in the first half of 2025, attributed to increased R&D investments and equity investment losses [52][53]. - 毛利率 (gross margin) has decreased due to price adjustments following the inclusion of key products in medical insurance [61][62]. Conclusion - 康方生物 is positioned for significant growth in the biopharmaceutical sector, with a robust pipeline and strategic focus on innovative therapies, while navigating challenges related to financial performance and market dynamics [2][4][8].

Core Viewpoint - Kangfang Biopharma reported a revenue of 1.412 billion yuan for the first half of 2025, marking a year-on-year increase of 37.75%, while the loss expanded to 588 million yuan from 249 million yuan in the same period last year [1][3] Financial Performance - Revenue for the period was 1.412 billion yuan, a 37.75% increase year-on-year [1] - Commercial sales revenue reached 1.402 billion yuan, up 49.20% year-on-year [1] - The company incurred a loss of 588 million yuan, which is an increase from the previous year's loss of 249 million yuan [1][3] Revenue Drivers - The growth in commercial sales revenue was primarily driven by the inclusion of AK104 and AK112 in the national medical insurance since January, leading to increased sales volume [1] - The increase in losses was attributed to a rise in equity investment losses from a partnership with Summit, which increased from 32.6 million yuan to 192 million yuan, as well as higher R&D expenses and stock incentive costs [3] Product Pipeline and Market Position - Kangfang Biopharma has received approval for seven products, including AK104 and AK112, which are key dual antibodies, and has expanded its commercial product range to include metabolic and autoimmune areas [4] - The sales team has grown from over 800 to 1,200 members, covering oncology and specialty drug sectors [4] - The company is focusing on AK112, which has shown promising results in clinical trials for non-small cell lung cancer [5][8] Clinical Development and Strategy - AK112 has achieved significant clinical endpoints in trials, including a statistically significant improvement in progression-free survival (PFS) [8][9] - The company is pursuing a strategy termed "IO2.0+ADC2.0," which aims to integrate dual antibodies with antibody-drug conjugates (ADCs) [12][13] - Kangfang Biopharma's pipeline includes ongoing clinical trials for various indications, with a focus on enhancing the efficacy of existing treatments [12][16]